• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Involving the Patient in Their Psoriasis Treatment With a 42-Year-Old Woman With a Busy Lifestyle

An expert discusses how treating busy professionals with scalp and nail psoriasis involves addressing injection anxiety, treatment adherence challenges, and the emotional impact of visible disease through health care provider–administered biologics.

The final case study presents a 42-year-old female marketing executive with long-standing plaque psoriasis since age 24, now progressing to affect her scalp and fingernails. This high-functioning professional faces significant stress, anxiety, and self-injection hesitancy, having previously used biologics including ustekinumab and secukinumab with inconsistent results due to missed doses and injection anxiety. Her demanding career leaves little personal time for consistent treatment management.

Scalp and nail psoriasis present unique treatment challenges that significantly impact professional patients. Scalp psoriasis affects over 50% of patients with plaque psoriasis and can be extremely difficult to treat with topicals, particularly for patients with certain hairstyles. Professional patients wearing dark clothing become self-conscious about visible flaking, and nail psoriasis affects emotional well-being and professional interactions. These areas are often recalcitrant to treatment, making biologic therapy essential for meaningful improvement.

Dr. Noor emphasizes the importance of addressing anxiety and depression in patients with psoriasis, noting the 3-fold increase in depression rates compared with the general population. For this patient, health care provider–administered tildrakizumab with 12-week dosing intervals provides an optimal solution, reducing injection anxiety while accommodating her busy schedule. Tildrakizumab demonstrates efficacy in treating difficult areas such as scalp and nails, offering quality-of-life improvements crucial for professional patients who need confidence in their appearance and social interactions.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
© 2025 MJH Life Sciences

All rights reserved.